Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R317573 efficacy on CCK-4–induced anxiety in healthy males
2006-001475-38Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of R317573 in anxiety disorder (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Efficacy of R317573 on CCK-4–induced anxiety. Started Mar 2006; status: completed.
02
Drugs
R317573
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on 2006-001475-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001475-38.